GILD Gilead Sciences Inc.

62.95
-0.3  -0%
Previous Close 63.25
Open 63.61
Price To Book 3.75
Market Cap 80254703200
Shares 1,274,896,000
Volume 11,551,116
Short Ratio
Av. Daily Volume 7,070,098

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 trial did not meet primary endpoint - February 11, 2019.
Selonsertib (GS-4997) - STELLAR 4
Nonalcoholic steatohepatitis (NASH)
Phase 2 enrollment completed 1Q 2018.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Sjogren’s syndrome
Phase 2 data 2Q 2018.
GS-9674
Primary sclerosing cholangitis
Phase 2 data released November 9, 2018.
GS-9674
Primary biliary cholangitis
Phase 2 trial to complete enrolment 4Q 2019.
GS-5734
Ebola
sNDA filed April 5, 2019. Likely PDUFA date under priority review of October 4, 2019.
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 2 enrolment to be completed 2Q 2020.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 2 data released September 6, 2018. Primary endpoint met.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 data released May 30, 2018 - primary endpoint met.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 3 futility analysis 3Q 2017. Trial to continue.
Andecaliximab GS-5745
Gastric Cancer
Approved February 7, 2018.
Bictegravir/F/TAF
HIV
Phase 2 data 4Q 2018.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 3 data due 2Q 2019.
Selonsertib (GS-4997) - STELLAR 3
Nonalcoholic steatohepatitis (NASH)
Phase 2 data released October 24, 2017. Positive high dose data, low dose negative.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)
Phase 2 ongoing.
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 initiated November 2016. Enrollment to be completed 2H 2019.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)
Regulatory filing 2H 2019.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 pivotal trial enrolment to be completed 2Q 2019.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 2 trial initiated 4Q 2018.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
2-year data at ASH 2018 noted 39% of patients were in an ongoing response. OS not yet reached.
Yescarta (axicabtagene ciloleucel)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
Phase 2 enrollment to be completed 3Q 2018.
KTE-C19 (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 trial to be initiated 4Q 2018.
KTE-C19 (ZUMA-8)
Chronic lymphocytic leukemia (CLL)
Phase 2 48-week data due 4Q 2019.
Selonsertib + Cilofexor (GS-9674) combo
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 3Q 2019.
GS-9131
HIV
Phase 3 enrollment to be completed 2H 2019.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 2 data April 11, 2019 noted median 37% reduction in alanine aminotransferase (ALT). Pruritus was not reported.
Cilofexor (GS-9674) and firsocostat (GS-0976) - ATLAS
Nonalcoholic steatohepatitis (NASH)

Latest News

  1. The Top 10 Biotechnology Companies (JNJ, ROG.VX)
  2. Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019
  3. Can Q1 Earnings Lift Healthcare ETFs Higher?
  4. Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
  5. Jim Cramer Shares His Thoughts On AMD, Gilead, Nvidia And More
  6. Gilead Collaborates With Insitro to Develop NASH Therapies
  7. Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
  8. How This Biotech Giant Is Using Machine Learning In Liver Disease
  9. Why Amgen Stock Could Break Out to New Highs
  10. Gilead teams with startup to turn machine learning on fatty liver disease
  11. Gilead teams up with insitro for experimental NASH treatments
  12. Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
  13. Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
  14. Gilead to Collaborate with Novo Nordisk for NASH Treatment
  15. Goldman Sachs's 20 best stocks to invest in now
  16. Better Buy: Gilead Sciences vs. Biogen
  17. Better Buy: Amgen vs. Gilead Sciences
  18. Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
  19. 8 Stocks May Jump on Takeovers as Market Nears Peak
  20. Novo Nordisk and Gilead team up to test fatty liver disease treatment